PAVmed Q2 net loss $13.3M ($0.74/share); Lucid EsoGuard rev $1.2M on 2,756 tests

PAVmed Inc.

2025-Q2 EPS reported $0.13 revenue$14,000

GAAP net loss $13.3M ($0.74 diluted EPS); non-GAAP adjusted loss $1.8M ($0.11/share).
Lucid processed 2,756 EsoGuard tests and recognized $1.2M revenue; CAC meeting on Medicare LCD set Sept 4.
Lucid raised $16.1M in public offering; Veris completed $2.5M direct equity financing at $35M pre-money valuation.
Veris advancing implantable monitor through FDA clearance; partnered with OSU-The James for Cancer Care Platform.
Cash $4.0M at June 30 vs $1.2M at Dec 31, 2024; operating expenses $4.7M including $0.2M stock comp.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.